Dr. DeWolfe is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1719 6th Avenue S
CIRC 312
Birmingham, AL 35294Phone+1 205-934-3866Fax+1 205-975-6255
Summary
- Director, UAB Epilepsy Monitoring Unit
Director, Neurology Sleep Center, Birmingham VA Medical Center
Education & Training
- University of Alabama Medical CenterFellowship, Clinical Neurophysiology, 2005 - 2006
- University of Alabama Medical CenterResidency, Neurology, 2002 - 2005
- Henry Ford Health/Henry Ford HospitalInternship, Transitional Year, 2001 - 2002
- Chicago College of Osteopathic Medicine at Midwestern UniversityClass of 2001
Certifications & Licensure
- AL State License 2002 - 2024
- FL State License 2006 - 2012
- MI State License 2001 - 2002
- American Board of Psychiatry and Neurology Neurology
- American Board of Psychiatry and Neurology Epilepsy
- American Board of Psychiatry and Neurology Sleep Medicine
Clinical Trials
- Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) Start of enrollment: 2013 Jan 01
- Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension Start of enrollment: 2013 Oct 01
Publications & Presentations
PubMed
- 82 citationsNew-onset refractory status epilepticus (NORSE) — The potential role for immunotherapyAyaz Khawaja, Jennifer L. DeWolfe, David Miller, Jerzy P. Szaflarski
Epilepsy & Behavior. 2015-06-01 - 40 citationsFMRI response to acute psychological stress differentiates patients with psychogenic non-epileptic seizures from healthy controls - A biochemical and neuroimaging biom...Jane B. Allendorfer, Rodolphe Nenert, Kathleen A. Hernando, Jennifer L. DeWolfe, Sandipan Pati
Neuroimage. Clinical. 2019-01-01 - 94 citationsCannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study.Jerzy P. Szaflarski, E. M. Bebin, Gary Cutter, Jennifer L. DeWolfe, Leon S. Dure
Epilepsy & Behavior. 2018-10-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: